Corcept Therapeutics Incorporated (CORT)
Stock Price:
$17.44 USD
-0.34 (-1.91%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.02B |
| Revenue (ttm) |
351.21M |
| Net Income (ttm) |
114.11M |
| Shares Out |
115.56M |
| EPS (ttm) |
0.94 |
| PE Ratio |
18.55 |
| Forward PE |
17.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$17.44 |
| Previous Close |
$17.78 |
| Change ($) |
-0.34 |
| Change (%) |
-1.91% |
| Day's Open |
17.89 |
| Day's Range |
17.35 - 17.93 |
| Day's Volume |
485,707 |
| 52-Week Range |
9.70 - 23.48 |
More Stats
| Market Cap |
2.02B |
| Enterprise Value |
1.61B |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
115.56M |
| Float |
104.20M |
| EPS (basic) |
0.99 |
| EPS (diluted) |
0.94 |
| FCF / Share |
1.50 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
5.39% |
| FCF Yield |
8.58% |
| Payout Ratio |
n/a |
| Shares Short |
19.04M |
| Short Ratio |
2.88 |
| Short % of Float |
18.27% |
| Beta |
0.70 |
| PE Ratio |
18.55 |
| Forward PE |
17.48 |
| P/FCF Ratio |
11.66 |
| PS Ratio |
5.74 |
| PB Ratio |
4.58 |
| Revenue |
351.21M |
| Operating Income |
140.99M |
| Net Income |
114.11M |
| Free Cash Flow |
172.83M |
| Net Cash |
401.85M |
| Net Cash / Share |
3.48 |
| Gross Margin |
85.70% |
| Operating Margin |
40.14% |
| Profit Margin |
32.50% |
| FCF Margin |
49.21% |
| ROA |
21.32% |
| ROE |
30.36% |
| ROIC |
41.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
1 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$17.75*
(1.78% upside)
Low
7.00
Current: $17.44
High
26.00
Target: 17.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 306 | 251 | 159 | 81.32 | 50.29 | 26.55 | 10.36 | 3.31 | - | - |
| Revenue Growth | 21.99% | 57.82% | 95.77% | 61.72% | 89.39% | 156.36% | 213.18% | - | - | - |
| Gross Profit | 301 | 246 | 156 | 79.26 | 48.93 | 25.67 | 10.21 | 3.22 | - | - |
| Operating Income | 112 | 89.50 | 52.86 | 10.18 | -3.44 | -27.62 | -41.50 | -36.27 | -32.33 | -27.44 |
| Net Income | 94.18 | 75.41 | 129 | 8.14 | -6.41 | -31.38 | -46.01 | -38.05 | -32.35 | -25.97 |
| Shares Outstanding | 114 | 115 | 114 | 111 | 107 | 101 | 99.82 | 93.02 | 83.31 | 68.34 |
| Earnings Per Share | 0.77 | 0.60 | 1.04 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 |
| EPS Growth | 28.33% | -42.31% | 1385.71% | - | - | - | - | - | - | - |
| Operating Cash Flow | 136 | 116 | 60.94 | 18.39 | 3.13 | -27.38 | -37.06 | -36.02 | -27.40 | -22.29 |
| Capital Expenditures | -1.09 | -0.30 | -0.42 | -0.19 | -0.02 | -0.17 | -0.13 | -0.15 | -0.03 | - |
| Free Cash Flow | 135 | 115 | 60.52 | 18.20 | 3.11 | -27.55 | -37.19 | -36.17 | -27.43 | -22.29 |
| Cash & Equivalents | 276 | 207 | 88.74 | 51.54 | 40.44 | 24.25 | 54.88 | 93.03 | 39.64 | 24.58 |
| Total Debt | 3.46 | - | - | 14.66 | 27.49 | 33.89 | 35.07 | 31.68 | - | - |
| Net Cash / Debt | 273 | 207 | 88.74 | 36.87 | 12.94 | -9.64 | 19.81 | 61.35 | 39.64 | 24.58 |
| Assets | 412 | 312 | 221 | 68.75 | 51.90 | 34.63 | 63.08 | 99.17 | 39.83 | 25.10 |
| Liabilities | 41.13 | 35.81 | 29.57 | 27.37 | 33.40 | 38.02 | 42.06 | 37.39 | 5.03 | 3.86 |
| Book Value | 371 | 276 | 191 | 41.38 | 18.50 | -3.39 | 21.02 | 61.78 | 34.81 | 21.24 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Corcept Therapeutics Incorporated |
| Country |
United States |
| Employees |
206 |
| CEO |
Joseph K. Belanoff |
Stock Information
| Ticker Symbol |
CORT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CORT |
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.